Elicio Therapeutics Inc. (9HA)
XMUN 
Summary
Elicio Therapeutics: Hoping To Capitalize On Massive KRAS Hype, But Time Is Running Out
Elicio Therapeutics (ELTX) is approaching a pivotal trial readout for its KRAS peptide vaccine, positioning 2026 as a critical year for KRAS therapies. Imminent data from ELTX's pipeline could be a significant catalyst, despite ongoing concerns about the company's cash position. Financial overview highlights a looming cash crisis, underscoring the importance of upcoming clinical milestones for ELTX.
Wall Street Analysts Predict a 42.28% Upside in Elicio Therapeutics (ELTX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 42.3% in Elicio Therapeutics (ELTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why
Elicio Therapeutics (ELTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Elicio Therapeutics Inc. (9HA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Elicio Therapeutics Inc. ever had a stock split?
Elicio Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Robert T. Connelly CEO | XMUN Exchange | US28657F1030 ISIN |
| US Country | 32 Employees | - Last Dividend | 2 Jun 2023 Last Split | 5 Feb 2021 IPO Date |
Overview
Elicio Therapeutics, Inc. is a pioneering clinical-stage biotechnology entity dedicated to advancing a diverse portfolio of novel immunotherapies aimed at combating cancer and other diseases. With its headquarters planted in Boston, Massachusetts, the company stands at the forefront of leveraging scientific innovation to address some of the most pressing medical challenges. By focusing on the development of therapeutic vaccines and adjuvants, Elicio Therapeutics endeavors to usher in a new era of cancer treatment, harnessing the body's immune response to target and eliminate cancer cells with unprecedented precision.
Products and Services
ELI-002: As the flagship product candidate, ELI-002 is an AMP therapeutic vaccine designed to combat KRAS-driven cancers, which represent a significant percentage of cancer cases, including pancreatic, colorectal, and lung cancers. This innovative approach seeks to activate the immune system against cancer cells expressing mutated forms of the KRAS protein.
ELI-004: Functioning as an AMP-modified CpG adjuvant, ELI-004 is a critical component of the ELI-002 vaccine regimen. It is engineered to enhance the body's immune response to the cancer-targeting agents, bolstering the overall efficacy of the therapeutic vaccine.
ELI-007: Targeting mutant BRAF-driven cancers, ELI-007 is a lymph node targeted AMP-peptide vaccine. By focusing on cancers characterized by mutations in the BRAF gene, this vaccine aims to stimulate a robust immune response against the mutated cells, offering new hope for patients with this specific cancer type.
ELI-008: ELI-008 is a multivalent lymph node targeted AMP-peptide vaccine designed for the treatment of cancers expressing mutated TP53. Recognizing the pivotal role of TP53 in tumor suppression, this vaccine approaches cancer treatment by activating the immune system specifically against TP53-mutated cancer cells.
ELI-005: As a vaccine candidate aimed at preventing COVID-19, ELI-005 represents Elicio Therapeutics’ foray into infectious disease, leveraging its expertise in immunotherapy to contribute to the global fight against the COVID-19 pandemic.
ELI-011: Focused on the treatment of hematological cancers, ELI-011 is being developed to target and eliminate cancerous cells within the blood and bone marrow. This therapeutic strategy embodies the company's commitment to expanding its cancer treatment portfolio to include blood cancers.
ELI-012: This mKRAS TCR T cell AMP-lifier design is aimed at enhancing the efficacy of mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. By amplifying the body’s T cell response to mutated KRAS proteins, ELI-012 seeks to improve treatment outcomes for patients battling these aggressive forms of cancer.
